STAT+: Pharmalittle: U.S. officials and Pfizer to meet over Covid-19 booster shots; FDA full approval for vaccines may not be a game changer

Good morning, everyone, and nice to see you again after we took an extended break. We hope the weekend respite was relaxing and invigorating. Certainly, it was interesting to watch the much-ballyhooed space tourism industry get a lift, of sorts. How many of you have booked a flight? As for us, we are coping with more earthly matters, such as our to-do list. No doubt, you can relate. So here are a few tidbits to get you going. Hope all goes well today, and do keep in touch. …

Pfizer (PFE) is expected to brief top U.S. government health officials Monday about the need for a Covid-19 vaccine booster shot after an unusual public spat between the company and federal officials over whether a third shot will be necessary, The Washington Post reports. Pfizer and BioNTech (BNTX) plan to seek regulatory approval for a booster within weeks because they anticipate people would need a third dose six to 12 months after receiving the two-shot regimen. But top U.S. health officials have not decided whether boosters will be necessary.

Continue to STAT+ to read the full story…

STAT+: Pharmalittle: U.S. officials and Pfizer to meet over Covid-19 booster shots; FDA full approval for vaccines may not be a game changer

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top